Abzena Appoints Lotta Ljungqvist As Non-Executive Director

Published: Sep 19, 2017

Cambridge, UK, 19 September 2017 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies to enable development and manufacture of biopharmaceutical products, announces that Lotta Ljungqvist has today been appointed as a Non-Executive Director of the Company.

Lotta Ljungqvist has a broad range of commercial and directorial experience. She currently holds a dual role as President and CEO of GE Nordics, responsible for GE’s growth in all sectors across the region. She is also CEO of BioProcess Innovation Hub, a government initiative, where she has been setting up a new facility aiming to support biotechnology companies in Scandinavia.

Before taking on the dual role at GE Nordics she spent eight years with GE Healthcare Life Sciences as its Global Head of R&D BioProcess. During this time, the division doubled in size due to a series of acquisitions.

Prior to this, Lotta was CEO of a start-up Biotech, IMED AB, based on research from the Karolinska Institute. She also worked at Biovitrum AB for six years, as SVP, Biopharmaceutical Process Development, selling cell culture, purification and analytical services to the biopharmaceutical sector.

Lotta has held several board positions including her current position as Non-Executive Director on the board of Atlas Antibodies, a privately held manufacturer and distributor of research antibodies and as Board Director of Vinnova, the Swedish government agency that administers state funding for research and development.

Dr Ken Cunningham, Abzena’s Chairman, said:

“Lotta has a deep understanding of biomanufacturing and development services, and how to support the needs of biopharmaceutical companies. As a result of her strategic and operational capability, to manage a contract development and manufacturing service business, she will be an invaluable asset to Abzena, as it aims to deliver value-adding services and technology solutions to its customers.”

If you are having issues with the directorship table, please see: http://www.abzena.com/news/abzena-appoints-lotta-ljungqvist-non-executive-director/

Abzena plc
+44 1223 903498
John Burt, Chief Executive Officer
Julian Smith, Chief Financial Officer

Numis (Nominated Adviser and Broker)
+44 20 7260 1000
Clare Terlouw / James Black / Paul Gillam

N+1 Singer (Joint Broker)
+44 20 7496 3000
Aubrey Powell / Liz Yong

Instinctif Partners
+44 20 7457 2020
Melanie Toyne Sewell / Alex Shaw / Deborah Bell

Notes To Editors

About Abzena

Abzena (AIM: ABZA) provides proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products.

The term ‘ABZENA Inside’ is used by Abzena to describe products that have been created using its proprietary technologies and are being developed by its partners, and include Composite Human AntibodiesTM; and ThioBridgeTM Antibody Drug Conjugates (ADCs). Abzena has the potential to earn future licence fees, milestone payments and/or royalties on ‘ABZENA Inside’ products.

Abzena offers the following services and technologies across its principal sites in Cambridge (UK), San Diego, California (USA) and Bristol, Pennsylvania (USA):

• Immunology research studies, including immunogenicity assessment of candidate biopharmaceutical products;

• Protein engineering to create humanized antibodies and deimmunised therapeutic proteins;

• Cell line development for the manufacture of recombinant proteins and antibodies;

• Contract process development and GMP manufacture of biopharmaceuticals, including monoclonal antibodies and recombinant proteins for preclinical and clinical studies;

• Contract synthetic chemistry and bioconjugation research services, focused on antibody-drug conjugates (ADCs);

• Proprietary site-specific conjugation technologies and novel payloads for ADC development; and

• GMP manufacturer of ADC linkers, payloads & combined linker-payloads.

For more information, please see www.abzena.com

Back to news